FDA Okays Pfizer’s Embeda Extended Release Capsules and 2 Other Hot Stocks to Watch

Pfizer Inc. (NYSE:PFE): Current price $31.24

Pfizer has announced that the FDA has given a nod t0 a Prior Approval Supplement for Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. The Supplement included an update to the Embeda manufacturing process, addressing the pre-specified stability requirement that caused the voluntary recall of Embeda from the market in March 2011. Pfizer expects product availability in the second quarter of next year.


Sprint Nextel Corp. (NYSE:S): Current price $7.26

On Tuesday, Sprint and Vantiv Inc. debuted a tablet-based, cloud-connected point-of-sale system. Vantiv Mobile Checkout, which is powered by NCR Silver, facilitates and makes it more affordable for businesses to switch from traditional cash registers and manual processes to the latest integrated tech. Vantiv Mobile Checkout, available via the Sprint business sales channel, allows business owners to monitor sales and profitability, analyze and report on customer patterns, manage inventory, market to customers and process sales on site or on location using secure payment processing.


GT Advanced Technologies Inc. (NASDAQ:GTAT): Current price $9.895

On Monday, GT agreed to provide sapphire material to Apple Inc., which employs sapphire crystal in the fingerprint readers for its iPhone 5S. The former expects to employ in excess of 700 workers. This multiyear accord must have a minimum level of capacity but it does not guarantee volumes, as such.


Don’t Miss: Riding an Earnings High, Ford Turns to the Middle East and Africa.